How to appeal an Aetna ms treatments denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna ms treatments denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for ms treatments
Cited policy: Aetna Clinical Policy Bulletin - Multiple Sclerosis: Pharmacologic Therapies
Definite MS per 2017 McDonald criteria. Documented relapsing course or PPMS with MRI activity. High-efficacy agents typically require inadequate response/intolerance/contraindication to two preferred DMTs. Tysabri: TOUCH + JCV. Aetna CPB 0746 lists autologous HSCT for MS as experimental/investigational.
How Aetna denies ms treatments — and how to counter it
Where Aetna pushes back: 1) Failure to document inadequate response to two preferred DMTs; 2) MRI not within 12 months; 3) HSCT denied per CPB 0746 as experimental; 4) Briumvi denied — Ocrevus required first.
Counter-arguments that hold up: CPB 0264 itself acknowledges AAN 2018 — invoke explicitly: AAN supports switching to higher-efficacy DMT after a single breakthrough event, NOT requiring two failures. CPB 0264 recognizes Ocrevus for PPMS — for PPMS denial cite this directly + ORATORIO. For Tysabri: JCV negative or index <0.9 + AFFIRM. For Briumvi: ULTIMATE I/II superiority to teriflunomide; non-formulary ≠ lack of medical necessity. For HSCT under CPB 0746: MIST (JAMA 2019), HALT-MS (JAMA Neurol 2017), EBMT/ASTCT 2020 — establish HSCT for treatment-refractory RRMS as evidence-based not experimental.
What Aetna typically denies for ms treatments
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For ms treatments, expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the ms treatments treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Ocrevus
- Kesimpta
- Briumvi
- Tysabri
- Lemtrada
- S1P modulator
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna ms treatments denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for ms treatments?
For ms treatments, Aetna most often denies on: 1) Failure to document inadequate response to two preferred DMTs; 2) MRI not within 12 months; 3) HSCT denied per CPB 0746 as experimental; 4) Briumvi denied — Ocrevus required first. The strongest counters: CPB 0264 itself acknowledges AAN 2018 — invoke explicitly: AAN supports switching to higher-efficacy DMT after a single breakthrough event, NOT requiring two failures. CPB 0264 recognizes Ocrevus for PPMS — for PPMS denial cite this directly + ORATORIO. For Tysabri: JCV negative or index <0.9 + AFFIRM. For Briumvi: ULTIMATE I/II superiority to teriflunomide; non-formulary ≠ lack of medical necessity. For HSCT under CPB 0746: MIST (JAMA 2019), HALT-MS (JAMA Neurol 2017), EBMT/ASTCT 2020 — establish HSCT for treatment-refractory RRMS as evidence-based not experimental.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your MS treatments appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com